Download by
Scanning QR Code
  • Download app

    Download app

You've successfully got advanced quotes worth 5000 HKD
Download APP >>


Huadong Pharmaceutical (000963.SZ): ELAHERE™, the world's first ADC drug for treating platinum-resistant ovarian cancer, plans to submit a BLA application to NMPA in the second half of the year

Gelonghui Finance ·  02/20 15:30

格隆汇2月20日丨华东医药(000963.SZ)于2023年2月15日14:30-16:00;2月16日11:00-11:40、14:00-15:00接受机构现场调研时表示,2022年11月15日,华东医药美国合作方ImmunoGen对外宣布,其用于治疗铂耐药卵巢癌的全球首创(first-in-class)ADC药物ELAHERE™ (mirvetuximab soravtansine-gynx,研发代码:IMGN853、HDM2002)获得美国食品药品监督管理局(FDA)加速批准上市。


Risk disclosure: The above content only represents the opinion of the authors or guests, and does not represent any positions of Futu or constitute any investment advice on the part of Futu. Before making any investment decision, investors should consider the risk factors related to investment products based on their own circumstances and consult professional investment advisers where necessary. Futu makes every effort to verify the authenticity, accuracy, and originality of the above content, but does not make any guarantees or promises.

    Write first comment